Axsome Therapeutics (AXSM) vs Corcept Therapeutics (CORT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Axsome Therapeutics (AXSM) has outperformed Corcept Therapeutics (CORT) over the past year, losing 13.4% versus a loss of 17.7%. Over five years, AXSM leads with a +250.4% price change compared with +196.0% for CORT. Corcept Therapeutics is the larger company by market cap ($6.96 billion vs $6.80 billion), about 1.0 times the size, while Axsome Therapeutics is growing revenue faster (+65.5% vs +12.8%).
On valuation, Corcept Therapeutics trades at a lower forward P/E (12.8x vs 35.5x for Axsome Therapeutics). Corcept Therapeutics converts more of its revenue into profit, with a net margin of 13.1% versus -28.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXSM | CORT |
|---|---|---|
| Share price | $129.36 | $63.62 |
| Market cap | $6.80B | $6.96B |
| 1-day change | -4.66% | -2.09% |
| YTD return | -29.17% | +82.82% |
| 1-year return | -13.44% | -17.69% |
| 5-year return | +250.38% | +196.04% |
| P/E ratio (TTM) | — | 47.83 |
| Forward P/E | 35.47 | 12.77 |
| EPS (TTM) | $-3.03 | $1.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $638.50M | $761.41M |
| Revenue growth (YoY) | +65.55% | +12.79% |
| Net income (latest FY) | $-183.17M | $99.65M |
| Gross margin | 92.56% | 98.30% |
| Operating margin | -26.12% | 5.88% |
| Net margin | -28.69% | 13.09% |
| 52-week high | $260.19 | $126.38 |
| 52-week low | $123.00 | $28.66 |
| Distance from 52-week high | -50.28% | -49.66% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +104.56% | +124.14% |
| Average volume | 865.33K | 1.26M |
| Shares outstanding | 52.60M | 109.44M |
| Employees | 1,390 | 730 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Corcept Therapeutics is more profitable, keeping 13.1 cents of every revenue dollar as net income versus -28.7 cents for Axsome Therapeutics.
- Axsome Therapeutics grew revenue faster in its latest fiscal year (+65.55% vs +12.79%).
About Axsome Therapeutics
AXSM stock →Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,390 employees
About Corcept Therapeutics
CORT stock →Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Health Care · Biotechnology: Pharmaceutical Preparations · 730 employees
AXSM vs CORT FAQ
Which is bigger, Axsome Therapeutics or Corcept Therapeutics?
Corcept Therapeutics (CORT) is larger, with a market capitalization of $6.96B compared with $6.80B for Axsome Therapeutics (AXSM).
Which stock has performed better over the past year, AXSM or CORT?
AXSM returned -13.44% over the past 12 months, compared with -17.69% for CORT (price return, excluding dividends). Past performance does not predict future results.
Are Axsome Therapeutics and Corcept Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.